Nippon Chemiphar Of Japan, Ranbaxy Of India To Part Ways On Nihon
This article was originally published in PharmAsia News
Japanese drug maker Nippon Chemiphar and India's Ranbaxy Laboratories are ending their nearly seven-year venture for selling generics in Japan. The two firms share equally in Nihon Pharmaceutical, which they created to market the generics made by Ranbaxy in India. Nippon Chemiphar, in the wake of fellow Japanese drug maker Daiicho Sankyo's purchase of Ranbaxy, now is negotiating with Ranbaxy to buy its 50 percent stake in Nihon. In addition to Ranbaxy's own review of its Japanese operations, the Nihon venture may not have been sufficiently profitable to satisfy Nippon Chemiphar. (Click here for more - a subscription may be required
You may also be interested in...
FDA warning to "Genesis II Church of Health and Healing " wasn't its first to the organization about promoting a chlorine dioxide formulation, "Miracle Mineral Solution," as an unapproved new drug. 'Infowars' host Alex Jones also was warned about bogus COVID-19 claims.
The first major revision since 2007 notably provides a legal foundation for special approvals under a public health crisis.
Resolution Medical teamed up with Carbon to introduce more than one million 3D-printed nasal swabs a week to address the shortage for COVID-19 testing.